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Abstract 
Objectives: Prasugrel and ticagrelor both reduce ischaemic endpoints in high-risk acute 
coronary syndromes, compared to clopidogrel. However, comparative outcomes of these two 
newer drugs in the context of primary PCI for ST elevation MI (STEMI) remains unclear. We 
sought to examine this question using the British Cardiovascular Interventional Society 
national database in patients undergoing primary PCI for STEMI. 
Methods: Data from January 2007 to December 2014 was used to compare use of P2Y12 
antiplatelet drugs in primary PCI in > 89,000 patients. Statistical modeling, involving 
propensity matching, multivariable logistic regression (MLR) and proportional hazards 
modeling, was used to study the association of different antiplatelet drug use with all-cause 
mortality.  
Results: In our main MLR analysis, prasugrel was associated with significantly lower mortality 
than clopidogrel at both 30-days (OR 0.87 95% CI 0.78-0.97, p=0.014) and 1-year (OR 0.89 
95% CI 0.82-0.97, P=0.011) post PCI. Ticagrelor was not associated with any significant 
differences in mortality compared to clopidogrel at either 30-days (OR 1.07 95%CI 0.95-1.21, 
P=0.237) or 1-year (OR 1.058 95%CI 0.96-1.16, P=0.247). Finally, ticagrelor was associated 
with significantly higher mortality than prasugrel at both time points (30-days, OR 1.22 95%CI 
1.03-1.44, P=0.020; 1-year OR 1.19 95% CI 1.04-1.35, P=0.01).  
Conclusions: In a cohort of over 89,000 patients undergoing primary PCI for STEMI in the 
UK, prasugrel is associated with a lower 30-day and 1-year mortality than clopidogrel and 
ticagrelor.  Given that an adequately powered comparative randomised trial is unlikely to be 
performed, these data may have implications for routine care. 
Keywords 
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Key Messages 
What is already known about this subject? 
Both prasugrel and ticagrelor have been shown to have clinical outcome benefit in large RCTs 
of heterogeneous populations with ACS. However, there have been no head-to-head adequately 
randomised comparisons of clinical outcomes for prasugrel versus ticagrelor in PPCI. 
What does this study add?  
We observe that prasugrel was associated with significantly lower mortality than clopidogrel 
at both 30-days and 1-year post PCI whilst ticagrelor was not associated with any significant 
differences compared to clopidogrel at these timepoints. Ticagrelor is associated with 
significantly higher mortality in PPCI than prasugrel at both time points.  
How this might impact on clinical practice?  
Our findings regarding the use of different P2Y12 antiplatelet agents in STEMI and their 
association with mortality is a timely and important contribution to the literature and one that 
may influence practice as best currently available evidence in the absence of a more definitive 
randomised controlled trial.  
 
 
 
 
 
 
 
 
 
 
Introduction 
Dual antiplatelet therapy using aspirin plus P2Y12 inhibitor agents such as clopidogrel in 
percutaneous coronary intervention (PCI) have improved clinical outcomes, with reductions in 
stent thrombosis and improved ischaemic outcomes1 2. However, there are important 
limitations with the use of clopidogrel.  Genetic variability in the enzymatic activation of 
clopidogrel is associated with functional ‘hypo’-responders to this drug, with individuals at 
increased risk of adverse ischaemic events3. The relatively slow onset of action, even with high 
dose loading regimens4, may be disadvantageous in the emergency setting of primary PCI for 
ST elevation myocardial infarction (STEMI). Such limitations stimulated the drive for novel 
P2Y12 inhibitors, including prasugrel and ticagrelor, offering faster onset and more potent 
inhibition of platelet activity. Both prasugrel and ticagrelor have been shown to have clinical 
outcome benefit in large randomised trials in a variety of acute coronary syndromes (ACS) 5 6 
albeit at increased risk of non-CABG related major bleeding. Use of these novel agents in the 
United Kingdom has been targeted in real world practice to those contexts where ischaemic 
risks are greatest, such as in primary PCI. It is notable that the post hoc analyses of both PLATO 
and TRITON TIMI 18 failed to show a statistically significant benefit for ticagrelor or 
prasugrel over clopidogrel in the primary PCI subgroups of their heterogeneous ACS 
populations7 8 and infact only 68% of the TRITON TIMI 18 STEMI cohort underwent primary 
PCI9.  
Although prasugrel and ticagrelor are both ADP-receptor antagonists, there are a number of 
differences between them, including their pharmacodynamics, drug interactions and side effect 
profile10. Switching between the two agents produces demonstrable changes in platelet 
function10 11. The landmark ACS trials (PLATO and TRITON) also found important 
differences in outcomes with these two drugs5 7. However, outcomes from these landmark trials 
cannot be directly compared due to important differences in study populations, study design 
and inclusion / exclusion criteria12.  
There has been no head-to-head randomised comparison of clinical outcomes for prasugrel 
versus ticagrelor until the recently presented PRAGUE-18 trial in STEMI and highest-risk 
NSTE-ACS13 in which no significant differences were observed in either the 7-day composite 
efficacy (primary) endpoint or the 30-day key safety endpoint. However, this trial was 
prematurely stopped after interim analysis and a severe statistical under-powering to address 
the planned aim. A trial of adequate power for a head to head comparison between  prasugrel 
versus ticagrelor would probably require a sample size approaching 15,000 patients14, with 
implications for the ISAR REACT 5 RCT aimed at addressing this question15.  
In the context of (a) limited data regarding comparative outcomes associated with ticagrelor 
and prasugrel use and (b) the unlikelihood of an adequately powered randomized trial to 
compare them in the future, our aim was to use the national British Cardiovascular Intervention 
Society (BCIS) PCI registry to explore outcomes associated with different P2Y12 antiplatelet 
agents in a large real world national cohort that captures >99% of PCI cases performed in the 
United Kingdom.  
Methods 
Study design and data collection 
This is a retrospective analysis of prospectively collected national data for all patients 
undergoing primary PCI in England and Wales from January 2007 to December 2014. BCIS 
records information on PCI practice in the UK with data collection managed by the National 
Institute of Cardiovascular Outcomes Research (NICOR)16-19. The BCIS database contains 113 
clinical, procedural and outcome variables with more than 80,000 new records added each year. 
Using the Medical Research Information Services, we tracked the life status of patients using 
their NHS number, a unique identifier for any person registered within the NHS.  All the data 
were collected as part of a national audit and were anonymised; therefore, institutional review 
board approval was not required for this study. 
Outcomes  
Our outcomes were mortality at 30 days and one year, In-hospital major bleeding complication 
and Major Adverse Cardiovascular Events (MACE), Bleeding complications were defined as 
a composite of reported gastrointestinal bleed, intracerebral bleed, retroperitoneal hematoma, 
tamponade, blood or platelet transfusion, or an arterial access site complication requiring 
intervention16 20 21, whilst a composite of in-hospital mortality, re-infarction and 
revascularization (emergency coronary artery bypass graft or re-intervention PCI) constituted 
MACE18 20.  
Study aim 
The primary aim of this study was to investigate the association between the use of a particular 
antiplatelet drug (clopidogrel, prasugrel and ticagrelor) and 30-day and 1-year mortality. 
Statistical analysis 
Patient exclusion criteria 
The data presented relate to all reported Primary PCI procedures undertaken in patients in 
England and Wales between January 1, 2007, and December 31, 2014. Procedures were 
excluded if outcome data, age, or gender were missing from the dataset.  
Descriptive statistics 
For basic analyses of demographics, procedural details and unadjusted outcomes, continuous 
variables were evaluated as median and interquartile range (IQR, whilst categorical variables 
were reported using frequencies and proportions (in percentages). Medians, IQRs, frequencies 
and percentages quoted for unadjusted data refer to numbers within the cohort where data were 
available. Chi-squared tests were used to assess the significance of differences in proportions 
between groups for categorical variables. Kruskal-Wallis rank sum test was used for continuous 
variables. All statistical tests were two-tailed and an alpha of 5% (for significance) was used 
throughout. 
Multiple imputations for missing data 
Multiple imputation methods were used in order to reduce potential bias created by missing 
data22. To this aim, we used the mice R package, version 2.2523 which is freely available on the 
The Comprehensive R Archive Network (CRAN) repository (https://cran.r-project.org). Chained 
equations were used to impute data for all variables with missing values to generate 10 dataset 
instances for use in the analyses. 
Multivariate statistical modelling 
Multivariate logistic regression models were performed over the multiple imputed dataset 
instances in order to elucidate associations, in the form of odd ratios, between antiplatelet drug 
selection and adverse outcomes. We also used multivariate Cox regression models to estimate 
hazard ratios between antiplatelet and survival time outcome censored to 1 year. In order to 
control for potential confounding, all models were adjusted for the following covariates: age, 
gender, smoking status, diabetes, history of peripheral vascular disease (PVD), hypertension, 
hypercholesterolemia, history of renal disease, previous coronary artery bypass graft (CABG), 
previous myocardial infarction (MI), previous stroke, previous PCI, left ventricular ejection 
fraction (LVEF), pre-procedural TIMI flow score, access site, vascular closure device (VCD) 
use, stent type, vessel attempted, cardiogenic shock (CS), intra-aortic balloon pump (IABP) 
use, ventilatory support, thrombectomy, glycoprotein IIb/IIIa inhibitors (GPI) use, bivalirudin 
use, and year of procedure. 
Propensity score matching 
A sensitivity analysis was performed using propensity score matching. The method was implemented 
in three separated logistic regression models (prasugrel vs clopidogrel, ticagrelor vs clopidogrel, 
and ticagrelor vs prasugrel) over the multiple imputed dataset instances using the 
aforementioned variables as explanatories and the antiplatelet drug use as the outcome. We 
used the MatchIt R package, version 2.4-2124, to estimate the propensity scores and to form the 
new matched dataset instances according to them. As initial settings, we used the nearest-
neighbor matching method and no procedures were discarded. Depending on the type of 
outcome, binary or survival time, conditional logistic or Cox regression models were 
performed, respectively, over the matched dataset instances. 
Results 
A total of 125,424 primary PCI procedures were undertaken on patients in England and Wales 
between 2007 and 2014 of which 89,067 (71.0 %) were included in the descriptive analyses 
and statistical modeling. Figure 1 displays a detailed flowchart for procedure 
inclusion/exclusion criteria, the commonest reasons being that antiplatelet agent was unknown 
in 34,265 procedures (27.42%). 
  
Figure 2 provides details on antiplatelet agent in primary PCI use at primary care trusts (PCTs, 
England) and local health boards (LHBs, Wales) levels.  This figure shows differences in use 
across England and Wales over time, ticagrelor mainly being prescribed in northern England 
and in some parts of the London area, whilst prasugrel seems to be favored in west England 
and some LHBs in Wales. 
  
Table 1 presents baseline patient demographics, procedural details, pharmacology and 
outcomes for the three antiplatelet groups. Supplementary Table S1a gives details of missing 
value levels presented in the data and Supplementary Table S1b patient demographics, 
procedural details, pharmacology and outcomes for patients where antiplatelet regime was 
missing. Results of statistical tests included in Table 1 illustrate significant differences amongst 
the groups. For instance, patients from the clopidogrel group were older and more likely to be 
female, and to have a history of peripheral vascular disease, hypertension, 
hypercholesterolemia, renal disease, coronary artery bypass graft, myocardial infarction, stroke, 
or PCI. Patients prescribed with prasugrel are younger, more likely to be male and current 
smokers, and less likely to be diabetics, whilst patients in the ticagrelor group were more likely 
to be non-smokers.  
Differences in procedural characteristics between the 3 groups were also observed, with 
procedures within the clopidogrel group less likely to be undertaken through the radial route, 
more likely to have multivessel PCI and present with cardiogenic shock and to require the use 
of intra-aortic balloon pump, although less likely to receive thrombectomy. Procedures within 
the prasugrel group were more likely to have patients with TIMI 0 flow, but less likely to 
require ventilatory support, whilst drug eluting stents were more likely to be used within the 
ticagrelor group. In addition, the use of bivalirudin is considerably less frequent within the 
clopidogrel group whilst glycoprotein IIb/IIIa inhibitors are less likely used within the 
ticagrelor group.  
Crude mortality at both 30 days and 1 year were highest in patients treated with clopidogrel 
(6.5% and 10.2% respectively); P<0.0001 and lowest in patients treated with prasugrel (3.6% 
and 5.9%); P<0.0001 (ticagrelor 5.5% and 8.5%); P<0.0001. Similarly, in-hospital MACE was 
significantly lower in the prasugrel group (3.2%) compared to either the group receiving 
clopidogrel (4.9%) or ticagrelor (4.8%); P<0.0001, whilst crude in-hospital bleeding rates were 
higher in the clopidogrel group (1.5%) compared to either prasugrel (0.7%) or ticagrelor 
(0.6%); P<0.0001. 
Table 2 shows the results of fitting multivariate logistic regression models to the original 
multiple imputed datasets. Compared with clopidogrel, prasugrel was associated with a lower 
risk of mortality at both 30 days (OR 0.87 95% CI 0.78-0.97, P=0.014) and 1 year (OR 0.89 
95% CI 0.82-0.97, P=0.011). prasugrel was also associated with decreased in-hospital major 
bleeding (OR 0.73 95% CI 0.59-0.91, P=0.005) although no significant differences in in-
hospital MACE were observed (OR 0.94 95% CI 0.84-1.06, P=0.30). In contrast, no significant 
differences in either 30-day (OR 1.07 95% CI 0.95-1.21, P=0.24) or 1-year mortality (OR 1.06 
95% CI 0.96-1.16, P=0.25) were observed between patients receiving ticagrelor compared to 
those receiving clopidogrel.  Finally, ticagrelor was associated with an increased risk of 30-day 
(OR 1.22, 95% CI 1.03-1.44, P=0.020) and 1-year (OR 1.19 95% CI 1.04-1.35) mortality 
compared to the prasugrel group. A similar increased risk of in-hospital MACE (OR 1.25, 95% 
CI 1.06-1.47, P=0.008) was observed associated with the use of ticagrelor compared with 
prasugrel although no significant differences in in-hospital major bleeding were observed.  
Figure 3 displays the Kaplan-Meier estimates of the survivor function for the 3 cohorts, and 
adjusted for the same set of covariates used before. Survival analyses were performed using 
multivariate Cox regressions in which the survival time outcome was censored at 1 year. Table 
3 summarizes the results, which shows associations between antiplatelet use and mortality. 
prasugrel was associated with a no significant difference in mortality compared to clopidogrel 
(HR 0.94 95% CI 0.87-1.01, P=0.084), whilst use of ticagrelor was associated with a significant 
increased mortality risk (HR 1.10 95% CI 1.02-1.19, P=0.019). Patients treated with ticagrelor 
also had a significantly greater risk of mortality than those patients receiving prasugrel (HR 
1.13 95% CI 1.01-1.27, P=0.030). 
A sensitivity analysis was performed by fitting conditional logistic and Cox regressions over 
10 propensity score matched dataset instances (Supplementary Table S2 that provides and 
overview of the propensity score matched datasets and Table 4) and in general the findings 
were materially similar, namely use of prasugrel was associated with a lower risk of mortality 
compared with ticagrelor, although no significant differences in mortality were demonstrated 
associated with the use of ticagrelor (compared to clopidogrel). Furthermore, prasugrel use was 
independently associated with a lower risk of mortality compared to ticagralor. Three further 
sensitivity analyses were performed using, firstly, a restricted dataset containing procedures 
undertaken since 2010, only, when all three antiplatelet drugs were available in the UK; and, 
secondly, a dataset which extends the prasugrel and ticagrelor group definitions to allow 
inclusion of procedures in which patients were prescribed clopidogrel as well as prasugrel, and 
clopidogrel aswell as ticagrelor (presumably reflecting pre-treatment with clopidogrel prior to 
prescription of either ticagrelor or prasugrel that was observed in 1.8% of cases), respectively. 
Finally, a third sensitivity analysis was undertaken by including the patients in whom the anti-
platelet status was unknown. Results from these analyses are presented in the supplementary 
material (supplementary Table S3-S5).  
 
Discussion 
Rationale for the present study 
Both prasugrel and ticagralor are associated with lower rates of ischaemic end points compared 
to clopidogrel in large randomised trials that included a heterogeneous population of ACS 
patients. However, two important questions that relate directly to clinical practice remain 
unclear. Firstly, whether the newer agents are significantly better than clopidogrel in a primary 
PCI population and secondly, the relative benefits of these 2 novel agents compared to each 
other.  
With a specific focus on STEMI, the landmark RCTs came to different conclusions in their 
relevant posthoc subgroup analyses. In the PLATO subgroup of patients treated with primary 
PCI within 12 hours for STEMI25, ticagrelor did not show a significant reduction in the primary 
efficacy endpoint versus clopidogrel, nor did it reduce cardiovascular death (in contrast to the 
overall study population). The possible reasons for this are various but include the smaller 
cohort size (around 4000 patients) compared to over 70,000 patients included in our analysis. 
Similarly, the TRITON subgroup who underwent primary PCI (with around 2300 patients) also 
demonstrated no significant reduction in the primary endpoint with prasugrel compared to 
clopidogrel9. We therefore attempted to evaluate the relative benefits of Prasugrel versus 
ticagrelor in primary PCI from a large observational registry and the present analysis provides 
the first comparative evaluation between prasugrel and ticagrelor in the “real world” from a 
national perspective. 
 
Interpreting key findings of our study 
Association of P2Y12 antagonist and clinical outcomes 
Certain baseline demographics are noteworthy when considering the association of oral 
antiplatelet agents and mortality in the present work. For example, radial access was far more 
frequently employed in patients receiving ticagrelor and prasugrel than in those receiving 
clopidogrel. The reasons behind this are not immediately clear but may be partly time-
dependent, since radial use in the UK progressively increased over the study period (2009-
2014)17 and a greater proportion of the clopidogrel cases were undertaken in the earlier part of 
this period compared to the other 2 agents.  Given the relationship between radial access and 
reduced major bleeding and mortality in STEMI21 26 27 this would favour outcomes in groups 
who received prasugrel and ticagrelor.  Furthermore, the group who received clopidogrel had 
a higher incidence of adverse risk factors for outcome, for example, evidence of cardiogenic 
shock at presentation and a history of previous stroke. Hence, it was not surprising to find that 
unadjusted (raw) data indicated both novel potent antiplatelets were associated with a 
significant mortality advantage over clopidogrel.  
After multivariate adjustment for differences in baseline co-variates, the significant mortality 
impact of the newer agents (each compared to clopidogrel) was found to persist for prasugrel 
but not ticagrelor. The mortality finding for prasugrel versus clopidogrel in our main adjusted 
analyses is interesting, since a reduction in the primary endpoint (of cardiovascular death, 
myocardial infarction, or stroke) at 15 months was also observed in the TRITON STEMI 
subgroup who underwent PCI (with around 3000 patients) with prasugrel compared to 
clopidogrel (HR 0.79, 95% CI 0.65 - 0.97; p = 0.022)9, although not in the primary PCI 
subgroup (HR 0.89, 95% CI 0.69-1.13). The primary PCI subgroup in TRITON was much 
smaller in size than ours (2340 versus over 70,000 cases), – hence it may simply be that the 
much larger population in our registry allowed a mortality effect too small to detect in the RCT 
to be demonstrated. Another pertinent factor arises from the likely pattern of use of prasugrel 
in our study versus that in TRITON. Given the real-world setting of our study, it is likely that 
prescribing guidance for prasugrel was largely followed and hence groups with neutral or 
adverse effect with prasugrel from TRITON were underrepresented in our study’s prasugrel 
group (as seen from patient age and history of stroke in Table 1). This too may have contributed 
to a larger advantage of prasugrel over clopidogrel in our work, compared to the landmark RCT. 
For the comparison of prasugrel versus ticagrelor, our mortality findings at both early (30 days) 
and later (1 year) time points favoured prasugrel in the main analysis.  Although there are 
potential unadjusted confounders or selection bias inherent in a study such as this, the 
differences described here may well reflect a genuine difference in clinical effect, rather than 
related to confounders or selection bias. Compliance may be a factor, since prasugrel is a once 
daily medication whereas ticagrelor has a b.d. regimen for use, and this may predispose to 
better adherence to prasugrel prescriptions. Another possible influence on compliance is the 
differing side effect profiles – for example, dyspnea sometimes noted with ticagrelor (but not 
prasugrel) might be a reason underlying non-compliance or unplanned switching to another 
agent, again potentially impacting on outcomes. Differences in pharmacodynamics between 
prasugrel and ticagrelor in patients presenting with STEMI may contribute to our findings28. 
For example, in one randomized study 2 h post loading dose ticagrelor achieved 12% platelet 
inhibition compared to 48% with prasugrel. Furthermore, the mean time to achieve platelet 
reactivity <240 units (using Accumetrics verifyNow) was 3±2h with prasugrel compared to 
5±4h in patients treated with ticagrelor28. In a  further analysis of 16,000 patients ACS managed 
with PCI treated with either prasugrel or ticagrelor, both MACE (HR 0.80, 95% CI 0.64–0.98, 
P= 0.03) and net adverse clinical events NACE (HR 0.78 95% CI 0.64–0.94, P= 0.009) were 
significantly lower in the prasugrel groups compared to ticagrelor in a propensity score 
matched cohort29. Similarly, a recent network meta-analysis of 37 studies including 88,402 
patients that sought to compare the clinical efficacy and safety of P2Y12 inhibitors in patients 
with STEMI undergoing primary PCI demonstrated that prasugrel was associated with reduced 
risk of 30-day mortality (OR 0.69, 95% CI 0.56-0.84) and 30-day MACE (OR 0.69, 95% CI 
0.56-0.84), but not cardiovascular mortality (OR 0.74, 95% CI 0.43-1.25) or major bleeding 
(OR 0.76 95% CI 0.57-1.05)30.  
Nevertheless, in keeping with all observational studies, the potential for undetected or 
unquantified confounders exists. An important limitation, specific to this work, relates to the 
recording of P2Y12 blocker choice on the registry database at the time of the primary PCI 
procedure. Hence, it is not possible to detect cases where there may have been premature drug 
discontinuation or substitution of the initially selected agent later in the clinical course e.g. due 
to side effects or whether the antiplatelet agent was given pre- or post-procedure. Thirdly, we 
acknowledge that there is likely to be selection bias, in that newer antiplatelet agents are more 
likely to be prescribed to less sick, younger patients that may drive some of our observations, 
although it is unlikely that such a mechanism would explain the differences in outcomes that 
we report between the 2 newer (prasugrel and ticagrelor) agents. Finally, our secondary 
endpoints (in hospital major bleeding and in-hospital MACE) are based on retrospective 
recording (by operators or other team members) of these complications and are not externally 
validated. This is in contrast to the highly robust mortality tracking, derived from linkage of 
the PCI registry to the national UK mortality database. Hence the conclusions drawn from these 
secondary endpoints are acknowledged to be less robust than our mortality outcomes. 
Conclusions 
In a cohort of just over 89,000 patients undergoing primary PCI for STEMI in clinical practice 
in the UK, prasugrel is associated with a lower 30 day and 1 year mortality than clopidogrel 
and ticagrelor.  Give that it is unlikely that an adequately powered randomized trial will be 
undertaken to compare them in the future, these data may have implications for routine clinical 
care.  
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 Table 1: Baseline patient demographics, procedural details, pharmacology, and outcomes. 
 Clopidogrel 
(58,248) 
Prasugrel 
(17,714) 
Ticagrelor 
(13,105) 
P-value† P-value‡ 
Age 64.0 (54.0 - 75.0) 61.0 (52.0 - 69.0) 63.0 (53.0 - 72.0) < 0.0001 < 0.0001 
Gender (Male) 42,821 (73.5%) 13,739 (77.6%) 9,721 (74.2%) < 0.0001 < 0.0001 
Smoking status < 0.0001 < 0.0001 
  Never 16,934 (32.3%) 4,797 (29.6%) 4,545 (37.6%)   
  Ex-smoker 15,465 (29.5%) 4,021 (24.8%) 2,742 (22.7%)   
  Current 20,033 (38.2%) 7,384 (45.6%) 4,785 (39.6%)   
Diabetes 8,233 (14.8%) 2,315 (13.4%) 1,927 (15.0%) < 0.0001 < 0.0001 
History of peripheral vascular disease 2,024 (3.6%) 416 (2.5%) 332 (2.7%) < 0.0001 0.21 
Hypertension 25,022 (44.9%) 6,363 (37.5%) 4,986 (40.5%) < 0.0001 < 0.0001 
Hypercholesterolemia 23,246 (41.7%) 6,850 (40.4%) 4,630 (37.6%) < 0.0001 < 0.0001 
History of renal disease 478 (0.9%) 67 (0.4%) 42 (0.3%) < 0.0001 0.34 
History of coronary artery bypass graft 1,866 (4.7%) 356 (2.5%) 367 (4.2%) < 0.0001 < 0.0001 
History myocardial infarction 7,603 (14.0%) 1,866 (10.7%) 1,472 (12.3%) < 0.0001 < 0.0001 
History of stroke 2,368 (4.2%) 322 (1.9%) 411 (3.3%) < 0.0001 < 0.0001 
History of percutaneous coronary intervention 5,642 (9.9%) 1,458 (8.3%) 1,120 (8.7%) < 0.0001 0.22 
Left ventricular ejection fraction < 0.0001 < 0.0001 
  Good (>50%) 10,098 (52.1%) 2,764 (55.8%) 1,978 (51.1%)   
  Moderate (30%-50%) 7,117 (36.7%) 1,763 (35.6%) 1,532 (39.6%)   
  Poor (<30%) 2,181 (11.2%) 427 (8.6%) 363 (9.4%)   
TIMI flow < 0.0001 < 0.0001 
  TIMI 0 35,718 (69.2%) 12,239 (75.8%) 8,140 (71.6%)   
  TIMI 1 4,660 (9.0%) 1,057 (6.5%) 964 (8.5%)   
  TIMI 2 5,031 (9.8%) 1,502 (9.3%) 1,101 (9.7%)   
  TIMI 3 6,189 (12.0%) 1,341 (8.3%) 1,161 (10.2%)   
Access site (Radial) 26,514 (47.1%) 12,692 (74.9%) 9,765 (78.3%) < 0.0001 < 0.0001 
Stent < 0.0001 < 0.0001 
  None 4,422 (8.0%) 1,050 (6.1%) 773 (6.1%)   
  Bare metal 19,479 (35.2%) 4,217 (24.5%) 1,503 (11.9%)   
  Drug eluting 31,492 (56.9%) 11,974 (69.5%) 10,381 (82.0%)   
Vessel attempted < 0.0001 < 0.0001 
  Venous or arterial graft 803 (1.4%) 259 (1.5%) 143 (1.1%)   
  Left main stem artery 411 (0.7%) 67 (0.4%) 230 (1.8%)   
  Left anterior descending artery 22,858 (39.5%) 6,905 (39.2%) 4,974 (38.2%)   
  Left circumflex artery 7,216 (12.5%) 2,186 (12.4%) 1,839 (14.1%)   
  Right coronary artery 22,915 (39.6%) 7,269 (41.2%) 5,147 (39.5%)   
  Multiple 3,671 (6.3%) 937 (5.3%) 700 (5.4%)   
Cardiogenic shock 4,155 (7.2%) 988 (5.6%) 812 (6.2%) < 0.0001 0.020 
Intra-aortic balloon pump use 2,832 (5.1%) 567 (3.4%) 421 (3.4%) < 0.0001 0.77 
Ventilatory support 1,891 (3.5%) 425 (2.5%) 392 (3.4%) < 0.0001 < 0.0001 
Thrombectomy 25,933 (46.6%) 8,583 (51.0%) 6,518 (52.7%) < 0.0001 0.005 
Bivalirudin use 5,095 (8.7%) 5,697 (32.2%) 2,963 (22.6%) < 0.0001 < 0.0001 
Glycoprotein IIb/IIIa inhibitors use 30,258 (53.7%) 7,672 (44.5%) 4,294 (34.8%) < 0.0001 < 0.0001 
Year < 0.0001 < 0.0001 
  2007 3,448 (5.9%) 0 (0.0%) 0 (0.0%)   
  2008 5,467 (9.4%) 0 (0.0%) 0 (0.0%)   
  2009 8,134 (14.0%) 42 (0.2%) 0 (0.0%)   
  2010 9,491 (16.3%) 1,649 (9.3%) 4 (0.0%)   
  2011 9,204 (15.8%) 4,383 (24.7%) 15 (0.1%)   
  2012 8,528 (14.6%) 5,049 (28.5%) 1,601 (12.2%)   
  2013 7,408 (12.7%) 3,594 (20.3%) 4,870 (37.2%)   
 Clopidogrel 
(58,248) 
Prasugrel 
(17,714) 
Ticagrelor 
(13,105) 
P-value† P-value‡ 
  2014 6,568 (11.3%) 2,997 (16.9%) 6,615 (50.5%)   
Bleeding 843 (1.5%) 121 (0.7%) 76 (0.6%) < 0.0001 0.30 
Major adverse cardiovascular event 2,783 (4.9%) 545 (3.2%) 616 (4.8%) < 0.0001 < 0.0001 
30 days mortality 3,534 (6.4%) 622 (3.6%) 689 (5.5%) < 0.0001 < 0.0001 
1 year mortality 5,656 (10.2%) 999 (5.9%) 1,075 (8.5%) < 0.0001 < 0.0001 
†Resulting tests when comparing the three groups. ‡Resulting tests when comparing Ticagrelor vs Prasugrel only. 
 
Table 2: Results of multivariate logistic regression models. Odd ratios, confidence intervals (in 
brackets), and p-values represent the pooled results over 10 multiple imputed dataset instances.   
Outcome Cohort Odd ratio (95% CI) P-value 
Bleeding Prasugrel vs Clopidogrel 0.732 (0.588-0.910) 0.005 
 Ticagrelor vs Clopidogrel 0.648 (0.493-0.852) 0.002 
 Ticagrelor vs Prasugrel 0.866 (0.600-1.249) 0.441 
MACE Prasugrel vs Clopidogrel 0.940 (0.837-1.056) 0.296 
 Ticagrelor vs Clopidogrel 1.171 (1.037-1.323) 0.011 
 Ticagrelor vs Prasugrel 1.249 (1.059-1.472) 0.008 
30 days mortality Prasugrel vs Clopidogrel 0.870 (0.777-0.973) 0.014 
 Ticagrelor vs Clopidogrel 1.074 (0.954-1.208) 0.237 
 Ticagrelor vs Prasugrel 1.216 (1.031-1.435) 0.020 
1 year mortality Prasugrel vs Clopidogrel 0.891 (0.815-0.974) 0.011 
 Ticagrelor vs Clopidogrel 1.058 (0.962-1.163) 0.247 
 Ticagrelor vs Prasugrel 1.188 (1.042-1.354) 0.010 
Table 3: Results of multivariate Cox regression models with survival time censored at 1 year. Hazard 
ratios, confidence intervals (in brackets), and p-values represent the pooled results over 10 multiple 
imputed dataset instances. 
Cohort Hazard ratio (95% CI) P-value 
Prasugrel vs Clopidogrel 0.935 (0.866-1.009) 0.084 
Ticagrelor vs Clopidogrel 1.099 (1.016-1.189) 0.019 
Ticagrelor vs Prasugrel 1.133 (1.012-1.267) 0.030 
 
 
 
 
 
Table 4: Sensitivity analysis 1 
(a) Results of conditional logistic regression models. Odd ratios, confidence intervals (in 
brackets), and p-values represent the pooled results over 10 propensity score matched 
dataset instances.   
Outcome Cohort Odd ratio (95% CI) P-value 
Bleeding Prasugrel vs Clopidogrel 0.737 (0.511-0.961) 0.031 
 Ticagrelor vs Clopidogrel 0.682 (0.464-1.005) 0.053 
 Ticagrelor vs Prasugrel 0.949 (0.515-1.748) 0.863 
MACE Prasugrel vs Clopidogrel 0.964 (0.814-1.141) 0.669 
 Ticagrelor vs Clopidogrel 1.219 (1.015-1.463) 0.034 
 Ticagrelor vs Prasugrel 1.309 (1.059-1.619) 0.013 
30 days mortality Prasugrel vs Clopidogrel 0.860 (0.738-0.998) 0.042 
 Ticagrelor vs Clopidogrel 1.099 (0.942-1.282) 0.229 
 Ticagrelor vs Prasugrel 1.281 (1.053-1.557) 0.013 
1 year mortality Prasugrel vs Clopidogrel 0.855 (0.755-0.968) 0.014 
 Ticagrelor vs Clopidogrel 1.082 (0.959-1.220) 0.201 
 Ticagrelor vs Prasugrel 1.250 (1.075-1.454) 0.004 
 
(b) Results of Cox regression models with survival time censored at 1 year. Hazard ratios, 
confidence intervals (in brackets), and p-values represent the pooled results over 10 
propensity score matched dataset instances. 
Cohort Hazard ratio (95% CI) P-value 
Prasugrel vs Clopidogrel 0.871 (0.774-0.981) 0.023 
Ticagrelor vs Clopidogrel 1.099 (0.971-1.243) 0.133 
Ticagrelor vs Prasugrel 1.258 (1.085-1.458) 0.002 
 
 
 



Supplementary Table S1: Proportion of missing values presents in the original dataset 
Variable Included (%) Missing (%) 
Age 89067 (100.0) 0 (0.0) 
Gender 89067 (100.0) 0 (0.0) 
Smoking status 80706 (90.6) 8361 (9.4) 
Diabetes 85706 (96.2) 3361 (3.8) 
History of peripheral vascular disease 85046 (95.5) 4021 (4.5) 
Hypertension 85046 (95.5) 4021 (4.5) 
Hypercholesterolemia 85046 (95.5) 4021 (4.5) 
History of renal disease 80681 (90.6) 8386 (9.4) 
History of coronary artery bypass graft 62921 (70.6) 26146 (29.4) 
History myocardial infarction 83847 (94.1) 5220 (5.9) 
History of stroke 85046 (95.5) 4021 (4.5) 
History of percutaneous coronary intervention 87548 (98.3) 1519 (1.7) 
Left ventricular ejection fraction 28223 (31.7) 60844 (68.3) 
TIMI flow 79103 (88.8) 9964 (11.2) 
Access site 85730 (96.3) 3337 (3.7) 
Stent 85291 (95.8) 3776 (4.2) 
Vessel attempted 88530 (99.4) 537 (0.6) 
Cardiogenic shock 88553 (99.4) 514 (0.6) 
Intra-aortic balloon pump use 85013 (95.4) 4054 (4.6) 
Ventilatory support 82589 (92.7) 6478 (7.3) 
Thrombectomy 84846 (95.3) 4221 (4.7) 
Bivalirudin use 89067 (100.0) 0 (0.0) 
Glycoprotein IIb/IIIa inhibitors use 85914 (96.5) 3153 (3.5) 
Year 89067 (100.0) 0 (0.0) 
Bleeding 87055 (97.7) 2012 (2.3) 
Major adverse cardiovascular event 87051 (97.7) 2016 (2.3) 
30 days mortality 85076 (95.5) 3991 (4.5) 
1 year mortality 85060 (95.5) 4007 (4.5) 
 
 
Supplementary Table S2: Quality of matching of propensity score matched dataset instances. 
 
Prasugrel vs Clopidogrel 
(332,000) 
Ticagrelor vs Clopidogrel 
(245,200) 
Ticagrelor vs Prasugrel 
(245,200) 
Variables Cases Controls Cases Controls Cases Controls 
Age 61.0 (52.0 - 69.0) 60.0 (51.0 - 70.0) 63.0 (54.0 - 73.0) 63.0 (53.0 - 74.0) 63.0 (54.0 - 73.0) 62.0 (54.0 - 70.0) 
Gender 128,640 (77.5%) 128,389 (77.3%) 90,830 (74.1%) 91,135 (74.3%) 90,830 (74.1%) 93,169 (76.0%) 
Smoking status       
  Never 49,881 (30.0%) 50,619 (30.5%) 46,674 (38.1%) 46,669 (38.1%) 46,674 (38.1%) 41,797 (34.1%) 
  Ex-smoker 41,608 (25.1%) 41,617 (25.1%) 28,173 (23.0%) 28,304 (23.1%) 28,173 (23.0%) 29,476 (24.0%) 
  Current 74,511 (44.9%) 73,764 (44.4%) 47,753 (39.0%) 47,627 (38.8%) 47,753 (39.0%) 51,327 (41.9%) 
Diabetes 22,194 (13.4%) 21,936 (13.2%) 18,426 (15.0%) 18,125 (14.8%) 18,426 (15.0%) 17,548 (14.3%) 
History of peripheral vascular disease 4,124 (2.5%) 4,194 (2.5%) 3,366 (2.7%) 3,309 (2.7%) 3,366 (2.7%) 3,152 (2.6%) 
Hypertension 62,496 (37.6%) 62,800 (37.8%) 49,750 (40.6%) 49,795 (40.6%) 49,750 (40.6%) 47,949 (39.1%) 
Hypercholesterolemia 67,499 (40.7%) 66,468 (40.0%) 46,162 (37.7%) 45,450 (37.1%) 46,162 (37.7%) 46,907 (38.3%) 
History of renal disease 758 (0.5%) 865 (0.5%) 441 (0.4%) 439 (0.4%) 441 (0.4%) 445 (0.4%) 
History of coronary artery bypass graft 4,859 (2.9%) 4,754 (2.9%) 4,622 (3.8%) 4,299 (3.5%) 4,622 (3.8%) 3,542 (2.9%) 
History myocardial infarction 17,872 (10.8%) 18,166 (10.9%) 14,857 (12.1%) 14,577 (11.9%) 14,857 (12.1%) 14,059 (11.5%) 
History of stroke 3,174 (1.9%) 3,580 (2.2%) 4,238 (3.5%) 4,174 (3.4%) 4,238 (3.5%) 2,882 (2.4%) 
History of percutaneous coronary intervention 13,906 (8.4%) 14,066 (8.5%) 10,551 (8.6%) 10,261 (8.4%) 10,551 (8.6%) 10,631 (8.7%) 
Left ventricular ejection fraction       
  Good (>50%) 96,820 (58.3%) 96,743 (58.3%) 63,299 (51.6%) 64,015 (52.2%) 63,299 (51.6%) 67,129 (54.8%) 
  Moderate (30%-50%) 57,276 (34.5%) 57,414 (34.6%) 49,250 (40.2%) 48,725 (39.7%) 49,250 (40.2%) 46,066 (37.6%) 
  Poor (<30%) 11,904 (7.2%) 11,843 (7.1%) 10,051 (8.2%) 9,860 (8.0%) 10,051 (8.2%) 9,405 (7.7%) 
TIMI flow       
  TIMI 0 125,587 (75.7%) 125,253 (75.5%) 87,725 (71.6%) 88,039 (71.8%) 87,725 (71.6%) 90,144 (73.5%) 
  TIMI 1 10,994 (6.6%) 11,153 (6.7%) 10,311 (8.4%) 10,430 (8.5%) 10,311 (8.4%) 9,044 (7.4%) 
  TIMI 2 15,494 (9.3%) 15,496 (9.3%) 11,912 (9.7%) 11,721 (9.6%) 11,912 (9.7%) 11,823 (9.6%) 
  TIMI 3 13,925 (8.4%) 14,098 (8.5%) 12,652 (10.3%) 12,410 (10.1%) 12,652 (10.3%) 11,589 (9.5%) 
Access site 124,145 (74.8%) 120,273 (72.5%) 96,558 (78.8%) 96,188 (78.5%) 96,558 (78.8%) 94,875 (77.4%) 
Stent       
  None 10,068 (6.1%) 10,181 (6.1%) 7,616 (6.2%) 7,594 (6.2%) 7,616 (6.2%) 7,617 (6.2%) 
  Bare metal 39,943 (24.1%) 39,273 (23.7%) 14,527 (11.8%) 14,868 (12.1%) 14,527 (11.8%) 15,601 (12.7%) 
  Drug eluting 115,989 (69.9%) 116,546 (70.2%) 100,457 (81.9%) 100,138 (81.7%) 100,457 (81.9%) 99,382 (81.1%) 
Vessel attempted       
  Venous or arterial graft 2,478 (1.5%) 2,370 (1.4%) 1,266 (1.0%) 1,271 (1.0%) 1,266 (1.0%) 1,460 (1.2%) 
 
Prasugrel vs Clopidogrel 
(332,000) 
Ticagrelor vs Clopidogrel 
(245,200) 
Ticagrelor vs Prasugrel 
(245,200) 
Variables Cases Controls Cases Controls Cases Controls 
  Left main stem artery 603 (0.4%) 639 (0.4%) 2,075 (1.7%) 1,767 (1.4%) 2,075 (1.7%) 603 (0.5%) 
  Left anterior descending artery 64,846 (39.1%) 64,875 (39.1%) 47,018 (38.4%) 47,148 (38.5%) 47,018 (38.4%) 48,171 (39.3%) 
  Left circumflex artery 20,628 (12.4%) 20,589 (12.4%) 17,507 (14.3%) 17,124 (14.0%) 17,507 (14.3%) 16,316 (13.3%) 
  Right coronary artery 68,704 (41.4%) 68,625 (41.3%) 48,246 (39.4%) 48,760 (39.8%) 48,246 (39.4%) 49,443 (40.3%) 
  Multiple 8,741 (5.3%) 8,902 (5.4%) 6,488 (5.3%) 6,530 (5.3%) 6,488 (5.3%) 6,607 (5.4%) 
Cardiogenic shock 9,190 (5.5%) 9,259 (5.6%) 7,735 (6.3%) 7,815 (6.4%) 7,735 (6.3%) 7,069 (5.8%) 
Intra-aortic balloon pump use 5,441 (3.3%) 5,451 (3.3%) 4,153 (3.4%) 4,201 (3.4%) 4,153 (3.4%) 3,963 (3.2%) 
Ventilatory support 4,103 (2.5%) 4,192 (2.5%) 4,134 (3.4%) 4,043 (3.3%) 4,134 (3.4%) 3,556 (2.9%) 
Thrombectomy 83,788 (50.5%) 84,718 (51.0%) 64,526 (52.6%) 62,955 (51.3%) 64,526 (52.6%) 63,383 (51.7%) 
Bivalirudin use 53,630 (32.3%) 39,284 (23.7%) 28,970 (23.6%) 25,869 (21.1%) 28,970 (23.6%) 32,494 (26.5%) 
Glycoprotein IIb/IIIa inhibitors use 74,041 (44.6%) 76,067 (45.8%) 41,926 (34.2%) 42,247 (34.5%) 41,926 (34.2%) 46,800 (38.2%) 
 
 
Supplementary Table S3: Sensitivity analysis 2 – Dataset restricted to years 2010 to 2014, only. 
(a) Results of logistic regression models. Odd ratios, confidence intervals (in brackets), and p-values 
represent the pooled results over 10 propensity score matched dataset instances. 
Outcome Cohort Odd ratio (95% CI) P-value 
Bleeding Prasugrel vs Clopidogrel 0.689 (0.535-0.888) 0.004 
 Ticagrelor vs Clopidogrel 0.587 (0.433-0.795) <0.001 
 Ticagrelor vs Prasugrel 0.958 (0.696-1.321) 0.795 
MACE Prasugrel vs Clopidogrel 0.882 (0.778-1.000) 0.051 
 Ticagrelor vs Clopidogrel 0.976 (0.865-1.101) 0.694 
 Ticagrelor vs Prasugrel 1.400 (1.233-1.589) <0.001 
30 days mortality Prasugrel vs Clopidogrel 0.813 (0.721-0.917) <0.001 
 Ticagrelor vs Clopidogrel 0.900 (0.805-1.005) 0.062 
 Ticagrelor vs Prasugrel 1.404 (1.247-1.581) <0.001 
1 year mortality Prasugrel vs Clopidogrel 0.814 (0.735-0.902) <0.001 
 Ticagrelor vs Clopidogrel 0.906 (0.825-0.995) 0.039 
 Ticagrelor vs Prasugrel 1.381 (1.254-1.520) <0.001 
 
(b) Results of Cox regression models with survival time censored at 1 year. Hazard ratios, confidence 
intervals (in brackets), and p-values represent the pooled results over 10 propensity score matched 
dataset instances. 
Cohort Hazard ratio (95% CI) P-value 
Prasugrel vs Clopidogrel 0.820 (0.742-0.905) <0.001 
Ticagrelor vs Clopidogrel 0.914 (0.835-0.999) 0.047 
Ticagrelor vs Prasugrel 1.386 (1.264-1.521) <0.001 
 
 
 
 
 
Supplementary Table S4: Sensitivity analysis 3 – Dataset Including procedures undertaken in patients 
with multiple antiplatelets§.  
(a) Results of logistic regression models. Odd ratios, confidence intervals (in brackets), and p-values 
represent the pooled results over 10 propensity score matched dataset instances.   
Outcome Cohort Odd ratio (95% CI) P-value 
Bleeding Prasugrel vs Clopidogrel 0.636 (0.481-0.842) 0.002 
 Ticagrelor vs Clopidogrel 0.552 (0.404-0.754) <0.001 
 Ticagrelor vs Prasugrel 0.933 (0.668-1.301) 0.681 
MACE Prasugrel vs Clopidogrel 0.892 (0.778-1.022) 0.099 
 Ticagrelor vs Clopidogrel 0.992 (0.880-1.119) 0.898 
 Ticagrelor vs Prasugrel 1.418 (1.246-1.614) <0.001 
30 days mortality Prasugrel vs Clopidogrel 0.833 (0.733-0.947) 0.005 
 Ticagrelor vs Clopidogrel 0.925 (0.826-1.036) 0.178 
 Ticagrelor vs Prasugrel 1.418 (1.256-1.601) <0.001 
1 year mortality Prasugrel vs Clopidogrel 0.823 (0.742-0.912) <0.001 
 Ticagrelor vs Clopidogrel 0.936 (0.853-1.026) 0.158 
 Ticagrelor vs Prasugrel 1.402 (1.270-1.548) <0.001 
 
(b) Results of Cox regression models with survival time censored at 1 year. Hazard ratios, confidence 
intervals (in brackets), and p-values represent the pooled results over 10 propensity score matched 
dataset instances. 
Cohort Hazard ratio (95% CI) P-value 
Prasugrel vs Clopidogrel 0.828 (0.750-0.915) <0.001 
Ticagrelor vs Clopidogrel 0.941 (0.862-1.028) 0.178 
Ticagrelor vs Prasugrel 1.406 (1.279-1.546) <0.001 
 
§ Patients prescribed both prasugrel and clopidogrel, and ticagrelor and clopidogrel were included in 
prasugrel and ticagrelor groups, respectively.  
 
 
 
Supplementary Table S5: Baseline patient demographics, procedural details, pharmacology, and 
outcomes including unknown antiplatelet prescription. 
 
Clopidogrel 
(58,248) 
Prasugrel 
(17,714) 
Ticagrelor 
(13,105) 
Unknown 
(27,344) 
P-value 
Age 64.4 (±13.4) 60.6 (±11.7) 63.0 (±12.9) 62.9 (±13.1) < 0.0001 
Gender (Male) 42,821 
(73.5%) 
13,739 
(77.6%) 
9,721 (74.2%) 20,261 
(74.1%) 
< 0.0001 
Smoking status     < 0.0001 
  Never 16,934 
(32.3%) 
4,797 (29.6%) 4,545 (37.6%) 8,835 (36.9%) 
 
  Ex-smoker 15,465 
(29.5%) 
4,021 (24.8%) 2,742 (22.7%) 5,821 (24.3%) 
 
  Current 20,033 
(38.2%) 
7,384 (45.6%) 4,785 (39.6%) 9,312 (38.9%) 
 
Diabetes 8,233 (14.8%) 2,315 (13.4%) 1,927 (15.0%) 3,296 (12.8%) < 0.0001 
History of peripheral vascular disease 2,024 (3.6%) 416 (2.5%) 332 (2.7%) 896 (3.4%) < 0.0001 
Hypertension 25,022 
(44.9%) 
6,363 (37.5%) 4,986 (40.5%) 9,682 (37.1%) < 0.0001 
Hypercholesterolemia 23,246 
(41.7%) 
6,850 (40.4%) 4,630 (37.6%) 9,370 (35.9%) < 0.0001 
History of renal disease 478 (0.9%) 67 (0.4%) 42 (0.3%) 211 (0.8%) < 0.0001 
History of coronary artery bypass 
graft 
1,866 (4.7%) 356 (2.5%) 367 (4.2%) 1,052 (5.3%) < 0.0001 
History myocardial infarction 7,603 (14.0%) 1,866 (10.7%) 1,472 (12.3%) 2,881 (12.0%) < 0.0001 
History of stroke 2,368 (4.2%) 322 (1.9%) 411 (3.3%) 972 (3.7%) < 0.0001 
History of percutaneous coronary 
intervention 
5,642 (9.9%) 1,458 (8.3%) 1,120 (8.7%) 2,124 (8.2%) < 0.0001 
Left ventricular ejection fraction     < 0.0001 
  Good (>50%) 10,098 
(52.1%) 
2,764 (55.8%) 1,978 (51.1%) 3,400 (43.6%) 
 
  Moderate (30%-50%) 7,117 (36.7%) 1,763 (35.6%) 1,532 (39.6%) 3,493 (44.8%) 
 
  Poor (<30%) 2,181 (11.2%) 427 (8.6%) 363 (9.4%) 910 (11.7%) 
 
TIMI flow     < 0.0001 
  TIMI 0 35,718 
(69.2%) 
12,239 
(75.8%) 
8,140 (71.6%) 14,182 
(74.1%) 
 
  TIMI 1 4,660 (9.0%) 1,057 (6.5%) 964 (8.5%) 1,175 (6.1%) 
 
  TIMI 2 5,031 (9.8%) 1,502 (9.3%) 1,101 (9.7%) 1,670 (8.7%) 
 
  TIMI 3 6,189 (12.0%) 1,341 (8.3%) 1,161 (10.2%) 2,106 (11.0%) 
 
Access site (Radial) 26,514 
(47.1%) 
12,692 
(74.9%) 
9,765 (78.3%) 14,375 
(54.7%) 
< 0.0001 
Stent     < 0.0001 
  None 4,422 (8.0%) 1,050 (6.1%) 773 (6.1%) 1,784 (7.2%) 
 
  Bare metal 19,479 
(35.2%) 
4,217 (24.5%) 1,503 (11.9%) 5,996 (24.1%) 
 
  Drug eluting 31,492 
(56.9%) 
11,974 
(69.5%) 
10,381 
(82.0%) 
17,111 
(68.7%) 
 
Vessel attempted     < 0.0001 
  Venous or arterial graft 803 (1.4%) 259 (1.5%) 143 (1.1%) 512 (1.9%) 
 
  Left main stem artery 411 (0.7%) 67 (0.4%) 230 (1.8%) 380 (1.4%) 
 
  Left anterior descending artery 22,858 
(39.5%) 
6,905 (39.2%) 4,974 (38.2%) 10,585 
(39.1%) 
 
  Left circumflex artery 7,216 (12.5%) 2,186 (12.4%) 1,839 (14.1%) 3,247 (12.0%) 
 
  Right coronary artery 22,915 
(39.6%) 
7,269 (41.2%) 5,147 (39.5%) 10,598 
(39.1%) 
 
  Multiple 3,671 (6.3%) 937 (5.3%) 700 (5.4%) 1,767 (6.5%) 
 
Cardiogenic shock 4,155 (7.2%) 988 (5.6%) 812 (6.2%) 2,553 (9.5%) < 0.0001 
Intra-aortic balloon pump use 2,832 (5.1%) 567 (3.4%) 421 (3.4%) 1,433 (5.6%) < 0.0001 
Ventilatory support 1,891 (3.5%) 425 (2.5%) 392 (3.4%) 1,726 (8.4%) < 0.0001 
Thrombectomy 25,933 
(46.6%) 
8,583 (51.0%) 6,518 (52.7%) 13,118 
(51.3%) 
< 0.0001 
Bivalirudin use 5,095 (8.7%) 5,697 (32.2%) 2,963 (22.6%) 996 (3.6%) < 0.0001 
Glycoprotein IIb/IIIa inhibitors use 30,258 
(53.7%) 
7,672 (44.5%) 4,294 (34.8%) 14,172 
(54.5%) 
< 0.0001 
Year     < 0.0001 
  2007 3,448 (5.9%) 0 (0.0%) 0 (0.0%) 915 (3.3%) 
 
  2008 5,467 (9.4%) 0 (0.0%) 0 (0.0%) 1,694 (6.2%) 
 
  2009 8,134 (14.0%) 42 (0.2%) 0 (0.0%) 2,859 (10.5%) 
 
  2010 9,491 (16.3%) 1,649 (9.3%) 4 (0.0%) 3,744 (13.7%) 
 
  2011 9,204 (15.8%) 4,383 (24.7%) 15 (0.1%) 4,415 (16.1%) 
 
  2012 8,528 (14.6%) 5,049 (28.5%) 1,601 (12.2%) 5,037 (18.4%) 
 
  2013 7,408 (12.7%) 3,594 (20.3%) 4,870 (37.2%) 4,420 (16.2%) 
 
  2014 6,568 (11.3%) 2,997 (16.9%) 6,615 (50.5%) 4,260 (15.6%) 
 
Bleeding 843 (1.5%) 121 (0.7%) 76 (0.6%) 315 (1.2%) < 0.0001 
Major adverse cardiovascular event 2,783 (4.9%) 545 (3.2%) 616 (4.8%) 1,410 (5.3%) < 0.0001 
30 days mortality 3,534 (6.4%) 622 (3.6%) 689 (5.5%) 1,931 (7.5%) < 0.0001 
1 year mortality 5,656 (10.2%) 999 (5.9%) 1,075 (8.5%) 2,788 (10.8%) < 0.0001 
 
